Fusen Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Dudu Cao
Chief executive officer
CN¥5.0m
Total compensation
| CEO salary percentage | 32.4% |
| CEO tenure | 12yrs |
| CEO ownership | 20.9% |
| Management average tenure | 5.8yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
There's Reason For Concern Over Fusen Pharmaceutical Company Limited's (HKG:1652) Price
Dec 18
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
May 21Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%
Mar 31Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
Dec 14Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly
Sep 02Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly
Apr 02A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns
Mar 06We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide
Feb 08
Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?
Jan 18Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?
Dec 28What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition
Dec 07If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns
Nov 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥90m |
| Mar 31 2024 | n/a | n/a | -CN¥63m |
| Dec 31 2023 | CN¥5m | CN¥2m | -CN¥36m |
| Sep 30 2023 | n/a | n/a | -CN¥24m |
| Jun 30 2023 | n/a | n/a | -CN¥11m |
| Mar 31 2023 | n/a | n/a | -CN¥23m |
| Dec 31 2022 | CN¥2m | CN¥2m | -CN¥35m |
| Sep 30 2022 | n/a | n/a | -CN¥34m |
| Jun 30 2022 | n/a | n/a | -CN¥34m |
| Mar 31 2022 | n/a | n/a | -CN¥9m |
| Dec 31 2021 | CN¥2m | CN¥2m | CN¥17m |
| Sep 30 2021 | n/a | n/a | CN¥48m |
| Jun 30 2021 | n/a | n/a | CN¥79m |
| Mar 31 2021 | n/a | n/a | CN¥75m |
| Dec 31 2020 | CN¥2m | CN¥1m | CN¥70m |
| Sep 30 2020 | n/a | n/a | CN¥67m |
| Jun 30 2020 | n/a | n/a | CN¥65m |
| Mar 31 2020 | n/a | n/a | CN¥59m |
| Dec 31 2019 | CN¥548k | CN¥516k | CN¥53m |
| Sep 30 2019 | n/a | n/a | CN¥63m |
| Jun 30 2019 | n/a | n/a | CN¥72m |
| Mar 31 2019 | n/a | n/a | CN¥87m |
| Dec 31 2018 | CN¥251k | CN¥242k | CN¥102m |
Compensation vs Market: Dudu's total compensation ($USD684.58K) is above average for companies of similar size in the Hong Kong market ($USD230.85K).
Compensation vs Earnings: Dudu's compensation has increased whilst the company is unprofitable.
CEO
Dudu Cao (38 yo)
12yrs
Tenure
CN¥4,997,000
Compensation
Mr. Zhiming Cao, also known as Dudu Cao is the Executive Director and Chief Executive Officer of Fusen Pharmaceutical Company Limited since January 18, 2013 and serves as its Chairman since November 04, 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Chairman | 12yrs | CN¥5.00m | 20.92% HK$ 123.7m | |
| Executive Director | no data | CN¥81.00k | no data | |
| Executive Director | no data | CN¥78.00k | no data | |
| Executive Director | no data | CN¥62.00k | no data | |
| Chief Financial Officer | 5.8yrs | no data | no data | |
| Company Secretary | less than a year | no data | no data |
5.8yrs
Average Tenure
52.5yo
Average Age
Experienced Management: 1652's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Chairman | 12yrs | CN¥5.00m | 20.92% HK$ 123.7m | |
| Executive Director | 7.8yrs | CN¥81.00k | no data | |
| Executive Director | 7.8yrs | CN¥78.00k | no data | |
| Executive Director | 7.8yrs | CN¥62.00k | no data | |
| Independent Non-Executive Director | 5.8yrs | CN¥162.00k | no data | |
| Independent Non-Executive Director | 6.6yrs | CN¥162.00k | no data | |
| Independent Non-Executive Director | 4.4yrs | CN¥162.00k | no data |
7.8yrs
Average Tenure
56yo
Average Age
Experienced Board: 1652's board of directors are considered experienced (7.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 01:26 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fusen Pharmaceutical Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|